Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea
Sol-Gel Technologies Ltd. (SLGL)
Last sol-gel technologies ltd. earnings: 11/13 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/markets/ipos/company/solgel-technologies-ltd-1031585-84610
Company Research
Source: GlobeNewswire
Patient enrollment of the pivotal Phase III Epsolay clinical trials is on schedule Top-line results expected in 2019 NESS ZIONA, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced today that it has completed enrollment of half of the patients in its pivotal Phase III clinical trials of Epsolay (formerly VERED) in subjects with papulopustular rosacea (also known as subtype II rosacea), a chronic, inflammatory skin condition that most often affects the face. Epsolay is a once-daily topical cream containing encapsulated benzoyl peroxide, 5%, using Sol-Gel’s proprietary microencapsulation technology. The pivotal Phase III clinical program is being conducted in accordance with Special Protocol Assessment (SPA) agreements with the U.S. Food and Dr
Show less
Read more
Impact Snapshot
Event Time:
SLGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLGL alerts
High impacting Sol-Gel Technologies Ltd. news events
Weekly update
A roundup of the hottest topics
SLGL
News
- Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream [Yahoo! Finance]Yahoo! Finance
- Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamGlobeNewswire
- Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]Yahoo! Finance
- Sol-Gel Technologies GAAP EPS of -$1.01 misses by $0.31, revenue of $1.55M misses by $0.85M [Seeking Alpha]Seeking Alpha
- Sol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsGlobeNewswire
SLGL
Earnings
- 11/9/23 - Beat
SLGL
Sec Filings
- 4/8/24 - Form SC
- 4/4/24 - Form 424B3
- 4/2/24 - Form EFFECT
- SLGL's page on the SEC website